Navigation Links
Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
Date:12/8/2012

COLUMBUS, Ohio Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.

The agent, ibrutinib (PCI-32765), is the first drug designed to target Bruton's tyrosine kinase (BTK), a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About 4,400 Americans die of the disease each year.

Study co-leader Dr. John C. Byrd, director of the division of hematology at Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) presented these findings today (12/8) at the 54th Annual Meeting of the American Society of Hematology (ASH) Annual Meeting in Atlanta, GA.

The study found that response to therapy was high across cohorts, with 71 percent of previously untreated older patients experiencing a complete or partial response at either treatment dose (420mg and 840mg). The same response was observed in 67 percent of the relapsed patients and half (50%) of the high-risk patient cohort. After 22 months of follow-up, the disease had not progressed in 96 percent of previously untreated patients and 76 percent of relapsed and high-risk patients.

"These findings are truly exciting because they demonstrate ibrutinib's potential as a highly active, well-tolerated first-line therapy for CLL that produces a high rate of durable remissions the remissions last months on end," Byrd says. "The drug is effective in part because patients are willing to stay on treatment since the side effects are very tolerable," he states.

Only non-severe side effects, including diarrhea, fatigue, chest infection, rash, nausea, joint pain and infrequent and transient low blood counts were observed. Investigators found no evidence of c
'/>"/>

Contact: Liz Bryan, Spectrum
lbryan@spectrumscience.com
443-506-1931
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. EzCheckPrinting Updated with New Category Feature to Simplify Check Printing and Tax Reporting
2. Winning the battle against leukaemia: Positive early results in clinical trial for DNA vaccine
3. Pure Cocoa Powder, the Key Ingredient in Dark Chocolate and Found in Diabetes Support Supplements has been Clinically Proven to Reduce Cardiovascular Risk
4. USC Norris cancer research ranks among top clinical advances for 2012
5. American Society of Clinical Oncology issues annual report on state of clinical cancer science
6. Clinical trial at GHSU Cancer Center targets advanced prostate cancer
7. Study finds link between access to online health information and use of clinical services
8. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
9. Molecular portraits of tumours match patients with trials in everyday clinical practice
10. New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
11. Spread of human melanoma cells in mice correlates with clinical outcomes in patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... promoting the establishment of telemedicine programs in communities throughout Georgia, announces the launch ... living in the rural communities of Hancock County, GA. The new program will ...
(Date:7/7/2015)... ... ... Dr. Poneh Ghasri , cosmetic dentist in Los Angeles, is now ... of the fastest, easiest ways to brighten a smile. Stained teeth can add years ... With the right teeth whitening treatment, patients can restore a more youthful appearance and ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... America is ... California Casualty’s Nominate A Hero program offers a special way to say ... well-deserving hero receives a $250 gift card and their place on the “Wall of ...
(Date:7/7/2015)... ... July 07, 2015 , ... Office Practicum ... company’s new Chief Financial Officer, effective July 6th, 2015. Ellen joins Office Practicum ... from a multi-billion dollar, global chemical company to early and growth-stage technology companies. ...
(Date:7/7/2015)... ... July 07, 2015 , ... Today’s ... managerial expertise to oversee large healthcare operations and their success is determined ... insurance companies, and regulators. American Sentinel University, an innovative, accredited provider of ...
Breaking Medicine News(10 mins):Health News:Georgia Partnership for TeleHealth prepares to Launch First Ambulance Telemedicine Solution in Georgia 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 3Health News:California Casualty Wants to Know: "Who Is Your Hero?" 2Health News:Office Practicum Announces new CFO 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 3Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 4
... A Centrelink decision to refuse disability support pension to a ... ,Matthew Pearce hailing from the Perth suburb of ... not to be permanent. ,Matthew was diagnosed with ... advice of a staff member from Centrelink. However last Friday ...
... epilepsy drug valproate poses a higher risk for fetal death ... ,Of the four epilepsy drugs tested in the study, ... 20 percent of the pregnancies exposed to valproate resulting in ... and brain, heart and lung problems. ,The rate ...
... the children and teenagers who had been immunised against epidemic ... infected// than those who haven't been vaccinated. ,Reports ... taken place among the young New Zealanders has resulted in ... disease. The officials from the Ministry of health have stated ...
... girls born to mothers who took the anti-miscarriage drug diethylstilbestrol ... breast cancer//, according to a new study published in the ... Researchers found that DES daughters over age 40 had 1.9 ... not exposed to the drug. ,They also found ...
... help them form connections with others, such as bringing ... of their own.// Even teens who acknowledge that ... motherhood early in life. Researchers have published observations ... ,"We need to help teen-agers ...
... was launched in China on 7th August,2006//. ,Cancer is ... of Health department’s report in May. It accounts for ... and lifestyle factors are responsible for 80% of the cancers ... Treatment extends the lives of 60% of the cancer patients ...
Cached Medicine News:Health News:"DES Daughters" Have High Risk Of Breast Cancer 2Health News:"DES Daughters" Have High Risk Of Breast Cancer 3Health News:Teens and Pregnancy 2Health News:Teens and Pregnancy 3
(Date:7/7/2015)... SHENZHEN, China , July 7, 2015 /PRNewswire/ -- ... ), a leading developer, manufacturer and marketer of ... to acquire the remaining stake in Wuhan Dragonbio ... million. Dragonbio is a domestic ... joint and other surgical products. Prior to today,s ...
(Date:7/7/2015)... 2015 EnteroMedics Inc. (NASDAQ: ETRM ), ... technology to treat obesity, metabolic diseases, and other gastrointestinal ... offering of 32,000,000 units. Each unit consists of one share ... purchase one share of common stock at a purchase ... units in the offering would result in them beneficially ...
(Date:7/7/2015)... July 7, 2015 Oasmia ... of drugs within human and veterinary oncology, today ... in the United States , ... leading companion animal therapeutic.      (Logo: ... ) , Paccal Vet-CA1 was ...
Breaking Medicine Technology:Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 2Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 3Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3Oasmia Pharmaceutical Launches US Brand and Sales Platform 2
... , , , ... service Contract Research Organization (CRO) founded in India, today announced the ... Application Suite (OLSAS) by going live with Oracle Siebel Clinical Trial ... , "We are excited to have the rollout of ...
... Aug. 5 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: ... a New Drug Submission (NDS) with the Therapeutic Products ... the antidepressant trazodone. , "We are pleased to file ... R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. ...
Cached Medicine Technology:SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite 2Labopharm files New Drug Submission with Health Canada for novel antidepressant 2Labopharm files New Drug Submission with Health Canada for novel antidepressant 3
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... reagent provides a long shelf life ...
... powder reagent once reconstituted offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... reagent provides a long shelf life ...
LCD chart display...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
Medicine Products: